CareDx to Report Fourth Quarter and Full Year 2024 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--February 11, 2025-- 

CareDx, Inc. (Nasdaq: CDNA) -- The Transplant Company$(TM)$ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today announced it will report financial results for the fourth quarter and full year 2024 after market close on Wednesday, February 26, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Individuals interested in listening to the conference call may do so by dialing 1-800-267-6316 for domestic callers or 1-203-518-9783 for international callers. Please reference Conference ID: CareDx. To listen to the webcast, please visit the Events & Presentations section of CareDx's Investor Relations website at: investors.caredx.com.

About CareDx -- The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250211346743/en/

 
    CONTACT:    CareDx, Inc. 

Investor Relations

Caroline Corner

investor@caredx.com

(END) Dow Jones Newswires

February 11, 2025 07:14 ET (12:14 GMT)